Crossmark

Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia

Crossref DOI link: https://doi.org/10.1016/j.reuma.2020.03.001

Published Print: 2021-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Sanchez-Pernaute, Olga http://orcid.org/0000-0002-9894-5699
Romero-Bueno, Fredeswinda I.

Selva-O’Callaghan, Albert
License Information

Text and Data Mining valid from 2021-11-01
More Information

This article is maintained by: Elsevier

Article Title: Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia

Journal Title: Reumatología Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reuma.2020.03.001

Content Type: simple-article

Copyright: © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.